Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo

Gene Therapy

Volumn 13, Issue 7, 2006, Pages 602-610

  Biglari, A ^a,b   Southgate, T D ^a   Fairbairn, L J ^a   Gilham, D E ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibody dependent cell cytotoxicity; Carcinoembryonic antigen; Immunotherapy; Monocytes; ScFv CD64 chimera

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD64 ANTIGEN; COMPLEMENTARY DNA; FC RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS VECTOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CELL SURVIVAL; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOSOL; GENE TRANSFER; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMOBILIZED CELL; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CARCINOMA; SURVIVAL RATE; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; CELLS, CULTURED; CYTOKINES; GENE THERAPY; GENETIC ENGINEERING; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MICE; MICE, NUDE; MONOCYTES; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECEPTORS, IGG; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS;

ADENOVIRIDAE; ANIMALIA;

EID: 33645102766     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302706     Document Type: Article

References (35)

1. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 2002; 196: 254-265.
2. Andreesen R, Scheibenbogen C, Brugger W, Krause S, Meerpohl HG, Leser HG et al. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: A new approach to cancer immunotherapy. Cancer Res 1990; 50: 7450-7456.
3. Brugger W, Scheibenbogen C, Krause S, Andreesen R. Large-scale production of human tumorcytotoxic macrophages grown from blood monocytes of cancer patients. Cancer Detect Prev 1991; 15: 407-412.
4. Eymard JC, Lopez M, Cattan A, Bouche O, Adjizian JC, Bernard J. Phase I/ II trial of autologous activated macrophages in advanced colorectal cancer. Eur J Cancer 1996; 32A: 1905-1911.
5. Hennemann B, Rehm A, Kottke A, Meidenbauer N, Andreesen R. Adoptive immunotherapy with tumor-cytotoxic macrophages derived from recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) mobilized peripheral blood monocytes. J Immunother 1997; 20: 365-371.
6. Andreesen R, Hennemann B, Krause SW. Adoptive immunotherapy of cancer using monocyte-derived macrophages: Rationale, current status, and perspectives. J Leukocyte Biol 1998; 64: 419-426.
7. Hennemann B, Beckmann G, Eichelmann A, Rehm A, Andreesen R. Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon gamma and lipopolysaccharide. Cancer Immunol Immunother 1998; 45: 250-256.
8. Monnet I, Breau JL, Moro D, Lena H, Eymard JC, Menard O et al. Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: A phase II study. Chest 2002; 121: 1921-1927.
9. Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci USA 1982; 79: 4761-4765.
10. Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T et al. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res 1988; 48: 1173-1179.
11. Dyall R, Vasovic LV, Clynes RA, Nikolic-Zugic J. Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor. Eur J Immunol 1999; 29: 30-37.
12. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 1998; 95: 652-656.
13. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19: 275-290.
14. Michon J, Moutel S, Barbet J, Romet-Lemonne JL, Deo YM, Fridman WH et al. In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc gamma RI bispecific antibody. Blood 1995; 86: 1124-1130.
15. Russoniello C, Somasundaram C, Schlom J, Deo YM, Keler T. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells. Clin Cancer Res 1998; 4: 2237-2243.
16. Goldstein J, Graziano RE, Sundarapandiyan K, Somasundaram C, Deo YM. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) × epidermal growth factor bispecific fusion protein. J Immunol 1997; 158: 872-879.
17. Chester KA, Begent RH, Robson L, Keep F, Pedley RB, Boden JA et al. Phage libraries for generation of clinically useful antibodies. Lancet 1994; 343: 455-456.
18. Gilham DE, O'Neil A, Hughes C, Guest RD, Kirillova N, Lehane M et al. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother 2002; 25: 139-151.
19. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989; 86: 10024-10028.
20. Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 1993; 178: 361-366.
21. Weijtens ME, Willemsen RA, Valerie D, Stam K, Bolhuis RL. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 1996; 157: 836-843.
22. Hombach A, Koch D, Sircar R, Heuser C, Diehl V, Kruis W et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Therapy 1999; 6: 300-304.
23. Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 2001; 248: 67-76.
24. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002; 20: 70-75.
25. Sheen AJ, Sherlock DJ, Irlam J, Hawkins RE, Gilham DE. T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches. Br J Cancer 2003; 88: 1119-1127.
26. Chester KA, Robson L, Keep PA, Pedley RB, Boden JA, Boxer GM et al. Production and tumour-binding characterization of a chimeric anti-CEA Fab expressed in Escherichia coli. Int J Cancer 1994; 57: 67-72.
27. Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 1996; 2: 979-984.
28. Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ et al. Redirecting mouse CTL against colon carcinoma: Superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J Immunol 2001; 166: 182-187.
29. Burke B, Sumner S, Maitland N, Lewis CE. Macrophages in gene therapy: cellular delivery vehicles and in vivo targets. J Leukocyte Biol 2002; 72: 417-428.
30. Repp R, van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C et al. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer 2003; 89: 2234-2243.
31. Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: Evaluation of four different scFvs and antigens. J Immunother 2005; 28: 203-211.
32. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997; 71: 1842-1849.
33. Lowenstein P, Shering A, Bain D, Castro M, Wilkinson G. The use of adenoviral vectors to transfer genes to identified target brain cells in vitro. In: Lowenstein P, Enquist L (eds). Protocols for Gene Transfer in Neuroscience: Towards Gene Therapy of Neurological Disorders. John Wiley and Sons: Hoboken, NJ, 1996, pp 93-114.
34. Southgate T, Kingston P, Castro M. Gene transfer into neural cells. In: Sibley D (ed). Current Protocols in Neuroscience. John Wiley and Sons: Hoboken, NJ, 2000, pp 23.21-24.23.40.
35. Dion LD, Fang J, Garver Jr RI. Supernatant rescue assay vs polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. J Virol Methods 1996; 56: 99-107.